Showing results (91-100 of 560) with videos related to
Sort By:
Pageof 56
Clinical Colorectal Cancer|December 6, 2007
The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancerDavid Watkins, David CunninghamCurrent Treatment Options in Oncology|November 17, 2017
The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction CancerElizabeth Cartwright, David CunninghamEuropean Journal of Cancer (Oxford, England : 1990)|August 1, 2009
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?Alicia Okines, David CunninghamClinical Colorectal Cancer|April 12, 2008
A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patientsChristopher Jackson, David CunninghamJournal of Geriatric Oncology|February 4, 2014
Bevacizumab in elderly patients with metastatic colorectal cancerFrancesco Sclafani, David CunninghamJournal of Clinical Medicine|January 13, 2021
The Mutational Concordance of Fixed Formalin Paraffin Embedded and Fresh Frozen Gastro-Oesophageal Tumours Using Whole Exome SequencingIrene Y Chong, Naureen Starling, Alistair Rust, et al.Journal for Immunotherapy of Cancer|November 19, 2019
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatmentAlice Newey, Beatrice Griffiths, Justine Michaux, et al.Oncotarget|January 8, 2019
Genomic loss of heterozygosity and survival in the REAL3 trialElizabeth C Smyth, Catherine Cafferkey, Andrea Loehr, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 20, 2019
MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal CancerShelize Khakoo, Paul David Carter, Gina Brown, et al.Clinical Colorectal Cancer|March 19, 2025
A Phase Two, Single-Arm, Open-Label Study With Dostarlimab Monotherapy in Participants With Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer (AZUR-1)Andrea Cercek, Jean-Baptiste Bachet, Jaume Capdevila, et al.Pageof 56